纤维支气管镜在儿童肺炎支原体肺炎治疗中的临床应用

Abstract
Figure/Table
References (18)
Related Citation (15)

Download: PDF (0 KB) HTML (48 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo explore the clinical application value of fiberbronchoscopy and bronchoalveolar lavage(BAL) in the treatment of Mycoplasma Pneumoniae pneumonia (MPP)children.MethodsTotally 123 children with segmental MPP and pulmonary atelectasis,who was hospitalized and underwent fiberbronchoscopy and BAL in the Pediatrics Department of our hospital from June 2015 to March 2017 were selected as the BAL group;52 children with segmental MPP complicated with atelectasis and whose family members of children with different purposes of fiberoptic bronchoscopy or BAL in our hospital department during the same period were selected as the control group.According to the random number,the BAL group was divided into two groups:62 cases with the odd number and treated with warm saline (37℃,0.5 ml/kg per time)as the NS group;61 cases with even numbers and and treated with warm NS (37℃,0.5 ml/kg per time)+Mucosolvan(1 mg/kg per time)as the Mucosolvan group.The fever time,hospital stay,hospital expenses,treatment total efficiency and so on of each group was compared.ResultsThere was mucosal congestion and edema of different degrees were found by fiberbronchoscopy in all children of the BAL group,mucosalfollicular hyperplasia in 20.3%cases, phlegm embolus in 15.4%cases,mucosal swelling,congestion and secondary stenosis in 26.0%cases,mucosal erosion in 4.1%cases,and congenital airway constriction in 2.4%cases.The fever time of BAL group was(5.6±1.4)d,hospitalization time was(13.3±1.7)d,medical expenses was(10 425.5± 121.8)yuan,the control group fever time was(8.3±1.7)d, hospitalization time was(15.7±1.5)d,medical expenseswas(11 034.7±148.3)yuan,and the BAL group was less than the control group(P＜0.05);the effective rate of BAL group was 98.4%,the control group was 88.5%,so the BAL group was significantly higher than that of the control group (P＜0.05).The fever time of Mucosolvan group was(5.5±1.6)d,NS group was(5.7±1.2)d,there were no significant differences between the two groups(P＞0.05).But the hospitalization time and medical cost in Mucosolvan group were(12.9±1.5)d and(10 122.5±125.7)yuan,both lower than those in NS group[(13.9±1.8)d,(10 725.3±109.5)yuan,(P＜0.05).The total effective rate was 98.4%in the two groups.ConclusionFiberbronchoscopy enables the detection of tracheal mucosal injury in children with segmental MPP,which provides better guidance for treatment.BAL can shorten the fever time and hospitalization time,reduce the medical costs and improve the therapeutic effect;and BAL with Mucosolvan Injection as solvent can further shorten the hospitalization time and reduce the medical costs.

Key words： Fiberbronchoscopy Mycoplasma Pneumoniae Mucosolvan Pneumonia Children

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Long-hui
	NING Ning
	KUANG Yun
	DING Guo-biao
	WU Xiao-ling
	LI Hai-yan

Cite this article:

WANG Long-hui,NING Ning,KUANG Yun, et al. Clinical application of fiber bronchoscope in the treatment of pediatric Mycoplasma Pneumoniae pneumonia[J]. 中国当代医药, 2017, 24(17): 72-76.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2017/V24/I17/72

[1]	Bamba M，Jozaki K，Sugaya N，et al.Prospective surveillance for atypical pathogens in children with community-acquired pneumonia in Japan[J].J Infect Chemother，2006，12（1）：36-41.
[2]	De Schutter I，De Wachter E，Crokaert F，et al.Microbiology of bronchoalveolar lavage fluid in children with acute nonresponding or recurrent community-acquired pneumonia：identification of nontypeable haemophilus influenzae as a major pathogen[J].Clin Iefect Dis，2011，52（12）：1437-1444.
[3]	中华医学会儿科学分会呼吸学组，《中华儿科杂志》编辑委员会.儿童社区获得性肺炎管理指南（2013修订）（上）[J].中华儿科杂志，2013，51（10）：745-752.
[4]	Xu YC，Zhu LJ，Xu D，et al.Epidemiological characteristics and meteorological factors of childhood Mycoplasma pneumoniate pneumonia in Hangzhou[J].World J Pediatr，2011，7（3）：240-244.
[6]	张冰，陈志敏.2000-2006年杭州市三岁以上儿童肺炎支原体肺炎临床特征变化趋势[J].中华儿科杂志，2010，48（7）：531-534.
[8]	Bezerra PGM，Britto MCA，Correia JB，et al.Viral and atypi-
[10]	Smith LG.Myeoplasma pneumonia and its complication[J]. Infect Dis Clin North Am，2010，24（1）：57-60.
[13]	罗征秀，罗健，李渠北，等.儿童支原体肺炎临床、影像学及纤维支气管镜诊治研究[J].第三军医大学学报，2010，32（2）：184-187.
[5]	Kawai Y，Miyashita N，Kubo M，et al.Nationwide surveillance of macrolide-resistantMycoplasma pneumonia infection in pediatric patients[J].Antimicrobial Agents and Chemontherapy，2013，57（8）：4046-4049.
[7]	Hong KB，Choi EH，Lee HJ，et al.Macrolide resistance of Mycoplasma pneumonia，South Korea，2000-2011[J].Emerging Infect Dis，2013，19（8）：1281-1284.
[9]	Jiang W，Yan Y，Ji W，et al.Cinical significance of different bacterial load of Mycoplasma pneumoninae pneumonia[J]. Brazilian J Infect Dis，2014，18（2）：124-128.
[11]	Narita M.Pathogensis of extrapulmonary manifestions of Mycoplasma pneumoniace infection with special reference to pneumonia[J].Infect Chemother，2010，16（3）：162-169.
[12]	Liu Y，Ye X，Zhang H，et al.Charicterization of macrolide resistance in Mycoplasma pneumonia isolated from children in Shanghai，China[J].Diagn Microbiol Infect Dis，2010，67（4）：355-358.
[14]	罗征秀，罗健，李渠北，等.儿童肺炎支原体肺炎急性期气道粘膜损害与预后关系[J].第三军医大学学报，2011，33（2）：190-193.
[15]	张永明，刘秀云，江载芳.儿童肺炎支原体肺炎合并肺不张发病率及预后研究[J].中国实用儿科杂志，2010，25（2）：143-146.
[16]	梁慧，韩青，田曼，等.纤维支气管镜在儿童肺炎支原体肺炎诊治中的应用[J].临床儿科杂志，2011，29（2）：122-126.
[17]	沈剑，俞珍惜.纤维支气管镜应用于儿童节段性肺炎支原体肺炎的疗效观察[J].临床儿科杂志，2012，30（11）：1036-1039.
[18]	曹国强，康军，韩爱军，等.经纤维支气管镜沐舒坦灌洗治疗感染性肺不张[J].中国内镜杂志，2006，12（8）：829-831.